Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma

Journal of Dermatology

Volumn 26, Issue 8, 1999, Pages 489-493

  Yamazaki, Naoya ^a   Yamamoto, Akifumi ^a   Wada, Takashi ^a   Ishikawa, Masashi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Combination chemotherapy; Japanese; Malignant melanoma; Response rates

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; NIMUSTINE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MALE; MELANOMA; NAUSEA; SKIN CANCER; TREATMENT OUTCOME; VOMITING;

EID: 0032831754     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1999.tb02033.x     Document Type: Article

References (16)

1. Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma, Melanoma Res, 3: 291-299, 1993.
2. Costanzi JJ, Vaitkevicius VK, Quagliana JM, et al: Combination chemotherapy for disseminated malignant melanoma, Cancer, 35: 342-346, 1975.
3. Seigler HS, Lucas VS Jr, Pickett NJ, et al: DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma, Cancer, 46: 2346-2348, 1980.
4. Ahn SS, Giuliano A, Kaiser L, et al: The limited role of BOLD chemotherapy for disseminated malignant melanoma, Proc Am Soc Clin Oncol, 2: 228, C-893, 1983.
5. Gundersen S: Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: A phase II study, Cancer Treat Rep, 71: 997-999, 1987.
6. Verschraegen CF, Kleeberg UR, Mulder J, et al: Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma, Cancer, 62: 1061-1065, 1988.
7. Legha SS, Ring S, Papadopoulos N, et al: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma, Cancer, 64: 2024-2029, 1989.
8. Del Prete SA, Maurer LH, O'Donnell J: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma, Cancer Treat Rep, 68: 1403-1405, 1984.
9. McClay EF, Mastrangelo MJ, Bellet RE: Combination chemohormonal therapy in the treatment of malignant melanoma, Cancer Treat Rep, 71: 465-469, 1987.
10. Tan EH, Ang PT: Combination chemotherapy (dacarbazine, carmustine, cisplatin, and tamoxifen) in advanced melanoma, Singapore Med J, 37: 165-167, 1996.
11. McClay EF, Mastrangelo MJ: Systemic chemotherapy for metastatic melanoma, Semin Oncol, 15: 569-577, 1988.
12. Rumke P, Kleeberg UR, MacKie RM, et al: Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC malignant melanoma cooperative group, Melanoma Res, 2: 153-156, 1992.
13. McClay EF, McClay MT, Albright KA, et al: Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma: A biologically important observation, Cancer, 72: 1914-1918, 1993.
14. Lemontt JF, Azzaria M, Gros P: Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells, Cancer Res, 48: 6348-6353, 1989.
15. Mann SP, Andrews DA, Howell SB: Modulation of cisplatin accumulation by forskolin in human ovarian carcinoma cells, Proc Am Assoc Cancer Res, 30: 1851, 1989.
16. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with decarbazine plus tamoxifen, N Eng J Med, 327: 516-523, 1992.